(Q38168903)

30 June 2019

title

Recent progress concerning CpG DNA and its use as a vaccine adjuvant (English)

1 reference

30 June 2019

author name string

Hidekazu Shirota

series ordinal

1 reference

30 June 2019

Dennis M Klinman

series ordinal

1 reference

30 June 2019

language of work or name

1 reference

26 November 2013

1 reference

30 June 2019

Expert Review of Vaccines

published in

1 reference

30 June 2019

volume

1 reference

30 June 2019

issue

1 reference

30 June 2019

page(s)

299-312

1 reference

30 June 2019

Approaching the asymptote? Evolution and revolution in immunology

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Immunotherapeutic uses of CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Plasmacytoid dendritic cells in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Natural type I interferon-producing cells as a link between innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Long-term effect of primary immunization on subsequent immune responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Synergy of CpG oligodeoxynucleotide and double-stranded RNA (poly I:C) on nitric oxide induction in chicken peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-ba

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Effect of CpG oligonucleotides on vaccine-induced B cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-ex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Cellular immunity in breast cancer patients completing taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Myeloid-derived suppressor cells: linking inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Pulmonary and cutaneous vasculitis following hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Theoretical and experimental approaches to generalized autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Toll-like receptor 9 in murine lupus: more friend than foe!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Liposomes to target the lymphatics by subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Multifunctional nanorods for gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs

21 January 2018

1 reference

12 December 2020

Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides

1 reference

12 December 2020

A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells

1 reference

12 December 2020

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

1 reference

12 December 2020

Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes

1 reference

12 December 2020

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

12 December 2020

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

12 December 2020

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

12 December 2020

Immunotherapy and chemotherapy--a practical partnership

1 reference

12 December 2020

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

1 reference

12 December 2020

The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.

1 reference

12 December 2020

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients

1 reference

12 December 2020

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans

1 reference

12 December 2020

BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation

1 reference

12 December 2020

Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

1 reference

12 December 2020

CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice

1 reference

12 December 2020

CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity

1 reference

12 December 2020

Cholera toxin - a foe & a friend.

1 reference

12 December 2020

Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection

1 reference

12 December 2020

Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA

1 reference

12 December 2020

CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL.

1 reference

12 December 2020

Do DNA vaccines induce autoimmune disease?

1 reference

12 December 2020

CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen

1 reference

12 December 2020

CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge

1 reference

12 December 2020

Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice

1 reference

12 December 2020

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

1 reference

12 December 2020

Suspected hepatitis B vaccination related vasculitis

1 reference

12 December 2020

Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.

1 reference

12 December 2020

10.1586/14760584.2014.863715

Identifiers

DOI

1 reference

30 June 2019

PMC publication ID

6335645

1 reference

30 June 2019

PubMed publication ID

24308579

1 reference

30 June 2019